NCT07673835Not yet recruitingPhase 2
Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）
Efficacy of Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer: A Single-Arm, Single-Center Phase II Trial
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
This study is a single-arm, single-center prospective clinical study that will evaluate the clinical feasibility and efficacy of immunotherapy combined with chemotherapy in the neoadjuvant treatment of ovarian cancer, in order to explore the progression-free survival of the study population.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- First submitted
- 14 Jun 2026
- Start date
- 6 Jun 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Obstetrics & Gynecology Hospital of Fudan University
- Diseases
- Ovarian cancer
- NCT number
- NCT07673835
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 49
- From 6 Jun 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnant women or patients whose most recent pregnancy was terminated within 2 weeks prior to screening.
- Prior treatment with immune checkpoint inhibitors or other immunomodulatory anticancer therapies.
- Major surgery within 4 weeks before study treatment, or planned major surgery during the study period.
- Unresolved ≥ Grade 2 toxicity (CTCAE v5.0) from prior anticancer therapy, excluding alopecia.
Other illness
- History of other malignancies within 3 years, except for adequately treated curable cancers (e.g., skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, or carcinoma in situ of the breast).
- Severe cardiovascular or cerebrovascular disease.
- Known hypersensitivity to study drugs or their components.
- Any condition that may compromise patient safety or interfere with study evaluation, as judged by the investigator.
Other
- Histological subtypes other than epithelial ovarian carcinoma, including mucinous carcinoma and clear cell carcinoma.
- Clinically significant hydronephrosis not amenable to stenting or nephrostomy, or presence of CNS metastases or carcinomatous meningitis.
Who the study is looking for
- Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma, FIGO 2014 stage III-IV disease;
- Female patients aged 18 to 75 years;
- Willing and able to provide written informed consent and comply with study visits and protocol-specified procedures;
- Candidates for cytoreductive surgery (debulking surgery);
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Estimated life expectancy of at least 6 months;
- Women of childbearing potential must agree to use effective contraception during the study period, and a negative serum or urine pregnancy test is required prior to enrollment;
- Adequate organ function.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Obstetrics and Gynecology Hospital of Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.